|1.||Doniņa, Simona: 1 article (10/2015)|
|2.||Venskus, Dite: 1 article (10/2015)|
|3.||Proboka, Guna: 1 article (10/2015)|
|4.||Jonsson, Björn: 1 article (10/2015)|
|5.||Strēle, Ieva: 1 article (10/2015)|
|6.||Auziņš, Jurgis: 1 article (10/2015)|
|7.||Alberts, Pēteris: 1 article (10/2015)|
|8.||Muceniece, Aina: 1 article (10/2015)|
|1.||Melanoma (Melanoma, Malignant)
10/01/2015 - "In conclusion, Rigvir significantly prolongs survival in early-stage melanoma patients without any side effect. "
10/01/2015 - "Rigvir significantly (P<0.05) prolonged survival in substage IB-IIC melanoma patients following surgery compared with patients who were under observation (according to current guidelines). "
10/01/2015 - "The present retrospective study was carried out to determine the effectiveness of Rigvir in substage IB, IIA, IIB and IIC melanoma patients on time to progression and overall survival. "
01/01/1992 - "The effect of rigvir, an immunomodulator of the viral origin, on cell-mediated immunity was studied in patients with skin malignant melanoma. "
01/01/1992 - "[The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir]."
|2.||Stomach Neoplasms (Stomach Cancer)